454228-69-4

Basic information

• Product Name: tert-butyl-4-(3-trifluoromethylphenyl)-5,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-butyl-4-(3-trifluoromethylphenyl)-5,6-dihydropyridine-1(2H)-carboxylate
• CAS NO: 454228-69-4
• Molecular Weight: 327.347
• Mol File: 454228-69-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl-4-(3-trifluoromethylphenyl)-5,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl-4-(3-trifluoromethylphenyl)-5,6-dihydropyridine-1(2H)-carboxylate(454228-69-4)
• EPA Substance Registry System: tert-butyl-4-(3-trifluoromethylphenyl)-5,6-dihydropyridine-1(2H)-carboxylate(454228-69-4)

Safety Data

• Hazardous Substances Data: 454228-69-4(Hazardous Substances Data)

Upstream product

• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1423-26-3 (meta-(trifluoromethyl)phenyl)boronic acid 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 

Downstream Products

• 65040-68-8 4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine 
• 32860-17-6 4-[3-(trifluoromethyl)phenyl]piperidine 

Relevant articles and documents

Compound as potassium channel modulator

The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.

Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists

Aryl-tetrahydropyridine derivatives were prepared and their PPARα/γ dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPARα/γ dual agonist with an EC50 of 1.73 and 0.64 μM in hPPARα and γ, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties.